SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'CIB'


List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1WG8_A_SAMA3142_0
(PREDICTED
S-ADENOSYLMETHIONINE
-DEPENDENT
METHYLTRANSFERASE)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H  45
GLY H  47
GLY H 128
ASP H  51
SER H  48
 None
CIB  H1001 (-4.4A)
None
None
CIB  H1001 (-4.2A)
 1.23A 1wg8A-1j2qH:
undetectable		 1wg8A-1j2qH:
22.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2B25_B_SAMB602_0
(HYPOTHETICAL PROTEIN)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
GLY H 128
SER H 129
VAL H  97
ILE H 113
 CIB  H1001 (-1.9A)
None
CIB  H1001 ( 4.8A)
None
None
 1.15A 2b25B-1j2qH:
undetectable		 2b25B-1j2qH:
21.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_2_BO221405_1
(PROTEASOME COMPONENT
PRE3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.33A 2f162-1j2qH:
28.8		 2f162-1j2qH:
28.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_H_BO2H1400_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  27
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.27A 2f16H-1j2qH:
29.6
2f16I-1j2qH:
28.1		 2f16H-1j2qH:
32.00
2f16I-1j2qH:
26.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.29A 2f16K-1j2qH:
29.6
2f16L-1j2qH:
24.9		 2f16K-1j2qH:
30.37
2f16L-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.34A 2f16N-1j2qH:
28.8		 2f16N-1j2qH:
28.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_V_BO2V1401_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  27
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.29A 2f16V-1j2qH:
29.6
2f16W-1j2qH:
28.2		 2f16V-1j2qH:
32.00
2f16W-1j2qH:
26.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.28A 2f16Y-1j2qH:
16.7
2f16Z-1j2qH:
24.6		 2f16Y-1j2qH:
30.37
2f16Z-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.34A 3mg02-1j2qH:
28.8
3mg0V-1j2qH:
29.7		 3mg02-1j2qH:
28.00
3mg0V-1j2qH:
32.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_H_BO2H1400_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
LYS H  33
ALA H  46
GLY H  47
ALA H  52
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
None
 1.31A 3mg0H-1j2qH:
29.7
3mg0I-1j2qH:
28.1		 3mg0H-1j2qH:
32.00
3mg0I-1j2qH:
26.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_H_BO2H1400_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
THR H  21
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.28A 3mg0H-1j2qH:
29.7
3mg0I-1j2qH:
28.1		 3mg0H-1j2qH:
32.00
3mg0I-1j2qH:
26.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		8 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
ALA H  46
GLY H  47
SER H 129
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
CIB  H1001 ( 4.8A)
 0.29A 3mg0K-1j2qH:
29.6
3mg0L-1j2qH:
24.8		 3mg0K-1j2qH:
30.37
3mg0L-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.34A 3mg0N-1j2qH:
28.9		 3mg0N-1j2qH:
28.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_V_BO2V1401_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  27
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.34A 3mg0V-1j2qH:
29.7
3mg0W-1j2qH:
28.1		 3mg0V-1j2qH:
32.00
3mg0W-1j2qH:
26.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		8 / 12 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
ALA H  46
GLY H  47
SER H 129
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
CIB  H1001 ( 4.8A)
 0.31A 3mg0Y-1j2qH:
16.6
3mg0Z-1j2qH:
24.4		 3mg0Y-1j2qH:
30.37
3mg0Z-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.78A 4qvlK-1j2qH:
29.7
4qvlL-1j2qH:
24.9		 4qvlK-1j2qH:
30.37
4qvlL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.27A 4qvlK-1j2qH:
29.7
4qvlL-1j2qH:
24.9		 4qvlK-1j2qH:
30.37
4qvlL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.76A 4qvlY-1j2qH:
16.7
4qvlZ-1j2qH:
24.7		 4qvlY-1j2qH:
30.37
4qvlZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.26A 4qvlY-1j2qH:
16.7
4qvlZ-1j2qH:
24.7		 4qvlY-1j2qH:
30.37
4qvlZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 9 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.74A 4qvmK-1j2qH:
29.6
4qvmL-1j2qH:
24.8		 4qvmK-1j2qH:
30.37
4qvmL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 9 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.29A 4qvmK-1j2qH:
29.6
4qvmL-1j2qH:
24.8		 4qvmK-1j2qH:
30.37
4qvmL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.74A 4qvmY-1j2qH:
16.7
4qvmZ-1j2qH:
24.6		 4qvmY-1j2qH:
30.37
4qvmZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.28A 4qvmY-1j2qH:
16.7
4qvmZ-1j2qH:
24.6		 4qvmY-1j2qH:
30.37
4qvmZ-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVN_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.37A 4qvnV-1j2qH:
29.7
4qvnb-1j2qH:
28.9		 4qvnV-1j2qH:
29.22
4qvnb-1j2qH:
28.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 9 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.28A 4qvnK-1j2qH:
29.7
4qvnL-1j2qH:
24.9		 4qvnK-1j2qH:
30.37
4qvnL-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVN_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.38A 4qvnH-1j2qH:
27.8
4qvnN-1j2qH:
28.9		 4qvnH-1j2qH:
29.22
4qvnN-1j2qH:
28.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 9 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.28A 4qvnY-1j2qH:
16.7
4qvnZ-1j2qH:
24.7		 4qvnY-1j2qH:
30.37
4qvnZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 10 ALA H  20
THR H  21
ALA H  27
LYS H  33
THR H  45
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
None
CIB  H1001 (-4.4A)
 0.87A 4qvpK-1j2qH:
29.6
4qvpL-1j2qH:
24.6		 4qvpK-1j2qH:
30.84
4qvpL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		7 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
THR H  45
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
None
CIB  H1001 (-4.4A)
 0.44A 4qvpK-1j2qH:
29.6
4qvpL-1j2qH:
24.6		 4qvpK-1j2qH:
30.84
4qvpL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 10 ALA H  20
THR H  21
ALA H  27
LYS H  33
THR H  45
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
None
CIB  H1001 (-4.4A)
 0.87A 4qvpY-1j2qH:
16.7
4qvpZ-1j2qH:
24.7		 4qvpY-1j2qH:
30.84
4qvpZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		7 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
THR H  45
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
None
CIB  H1001 (-4.4A)
 0.44A 4qvpY-1j2qH:
16.7
4qvpZ-1j2qH:
24.7		 4qvpY-1j2qH:
30.84
4qvpZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 9 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.32A 4qvqK-1j2qH:
29.6
4qvqL-1j2qH:
24.9		 4qvqK-1j2qH:
30.37
4qvqL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 9 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.31A 4qvqY-1j2qH:
16.7
4qvqZ-1j2qH:
24.7		 4qvqY-1j2qH:
30.37
4qvqZ-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVV_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
THR H  21
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.36A 4qvvH-1j2qH:
27.9		 4qvvH-1j2qH:
29.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 8 THR H   1
THR H  21
LYS H  33
GLY H  47
VAL H  49
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
CIB  H1001 (-4.0A)
 0.36A 4qvvK-1j2qH:
29.4
4qvvL-1j2qH:
24.8		 4qvvK-1j2qH:
30.84
4qvvL-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVV_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
THR H  21
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.36A 4qvvV-1j2qH:
29.8		 4qvvV-1j2qH:
29.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 8 THR H   1
THR H  21
LYS H  33
GLY H  47
VAL H  49
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
CIB  H1001 (-4.0A)
 0.35A 4qvvY-1j2qH:
16.5
4qvvZ-1j2qH:
24.6		 4qvvY-1j2qH:
30.84
4qvvZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.76A 4qvwK-1j2qH:
29.6
4qvwL-1j2qH:
24.8		 4qvwK-1j2qH:
30.37
4qvwL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.27A 4qvwK-1j2qH:
29.6
4qvwL-1j2qH:
24.8		 4qvwK-1j2qH:
30.37
4qvwL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.76A 4qvwY-1j2qH:
16.6
4qvwZ-1j2qH:
24.6		 4qvwY-1j2qH:
30.37
4qvwZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.26A 4qvwY-1j2qH:
16.6
4qvwZ-1j2qH:
24.6		 4qvwY-1j2qH:
30.37
4qvwZ-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVY_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
THR H  21
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.39A 4qvyH-1j2qH:
27.9		 4qvyH-1j2qH:
29.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.78A 4qvyK-1j2qH:
29.4
4qvyL-1j2qH:
24.8		 4qvyK-1j2qH:
30.37
4qvyL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
 0.25A 4qvyK-1j2qH:
29.4
4qvyL-1j2qH:
24.8		 4qvyK-1j2qH:
30.37
4qvyL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.78A 4qvyY-1j2qH:
16.5
4qvyZ-1j2qH:
24.6		 4qvyY-1j2qH:
30.37
4qvyZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
 0.25A 4qvyY-1j2qH:
16.5
4qvyZ-1j2qH:
24.6		 4qvyY-1j2qH:
30.37
4qvyZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		4 / 7 THR H   1
ALA H  20
THR H  21
LYS H  33
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
 0.31A 4qw0K-1j2qH:
29.2		 4qw0K-1j2qH:
30.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		4 / 7 THR H   1
ALA H  20
THR H  21
LYS H  33
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
 0.31A 4qw0Y-1j2qH:
16.4		 4qw0Y-1j2qH:
30.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.75A 4qw1K-1j2qH:
29.6
4qw1L-1j2qH:
24.9		 4qw1K-1j2qH:
30.37
4qw1L-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.28A 4qw1K-1j2qH:
29.6
4qw1L-1j2qH:
24.9		 4qw1K-1j2qH:
30.37
4qw1L-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.75A 4qw1Y-1j2qH:
16.6
4qw1Z-1j2qH:
24.6		 4qw1Y-1j2qH:
30.37
4qw1Z-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.27A 4qw1Y-1j2qH:
16.6
4qw1Z-1j2qH:
24.6		 4qw1Y-1j2qH:
30.37
4qw1Z-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.75A 4qw3K-1j2qH:
29.4
4qw3L-1j2qH:
24.7		 4qw3K-1j2qH:
30.37
4qw3L-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.30A 4qw3K-1j2qH:
29.4
4qw3L-1j2qH:
24.7		 4qw3K-1j2qH:
30.37
4qw3L-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.75A 4qw3Y-1j2qH:
16.5
4qw3Z-1j2qH:
24.5		 4qw3Y-1j2qH:
30.37
4qw3Z-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 10 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.29A 4qw3Y-1j2qH:
16.5
4qw3Z-1j2qH:
24.5		 4qw3Y-1j2qH:
30.37
4qw3Z-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 9 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.48A 4qwuK-1j2qH:
28.3
4qwuL-1j2qH:
24.6		 4qwuK-1j2qH:
30.37
4qwuL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 9 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.47A 4qwuY-1j2qH:
16.4
4qwuZ-1j2qH:
24.7		 4qwuY-1j2qH:
30.37
4qwuZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.75A 5bxnK-1j2qH:
29.7
5bxnL-1j2qH:
24.6		 5bxnK-1j2qH:
30.37
5bxnL-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.24A 5bxnK-1j2qH:
29.7
5bxnL-1j2qH:
24.6		 5bxnK-1j2qH:
30.37
5bxnL-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BXN_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
LYS H  33
ALA H  46
GLY H  47
ALA H  52
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
None
 1.29A 5bxnV-1j2qH:
29.9
5bxnW-1j2qH:
28.1		 5bxnV-1j2qH:
28.81
5bxnW-1j2qH:
26.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BXN_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
THR H  21
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.36A 5bxnV-1j2qH:
29.9
5bxnW-1j2qH:
28.1		 5bxnV-1j2qH:
28.81
5bxnW-1j2qH:
26.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.74A 5bxnY-1j2qH:
16.7
5bxnZ-1j2qH:
24.6		 5bxnY-1j2qH:
30.37
5bxnZ-1j2qH:
26.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.24A 5bxnY-1j2qH:
16.7
5bxnZ-1j2qH:
24.6		 5bxnY-1j2qH:
30.37
5bxnZ-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 9 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.23A 5d0xK-1j2qH:
29.6
5d0xL-1j2qH:
24.8		 5d0xK-1j2qH:
29.91
5d0xL-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 9 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.76A 5d0xK-1j2qH:
29.6
5d0xL-1j2qH:
24.8		 5d0xK-1j2qH:
29.91
5d0xL-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
THR H  21
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.36A 5d0xV-1j2qH:
29.8		 5d0xV-1j2qH:
29.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 9 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.24A 5d0xY-1j2qH:
16.6
5d0xZ-1j2qH:
24.6		 5d0xY-1j2qH:
29.91
5d0xZ-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 9 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.76A 5d0xY-1j2qH:
16.6
5d0xZ-1j2qH:
24.6		 5d0xY-1j2qH:
29.91
5d0xZ-1j2qH:
26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5JQ7_B_T0RB705_2
(ENVELOPE
GLYCOPROTEIN 2)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		4 / 7 LEU H 138
THR H   2
THR H   1
LEU H   6
 None
None
CIB  H1001 (-1.9A)
None
 1.05A 5jq7B-1j2qH:
undetectable		 5jq7B-1j2qH:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
THR H  21
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.29A 5l5zH-1j2qH:
27.9
5l5zI-1j2qH:
28.1		 5l5zH-1j2qH:
29.22
5l5zI-1j2qH:
26.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 9 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.41A 5l5zK-1j2qH:
29.6
5l5zL-1j2qH:
24.6		 5l5zK-1j2qH:
31.36
5l5zL-1j2qH:
26.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
THR H  21
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.29A 5l5zV-1j2qH:
29.8
5l5zW-1j2qH:
28.1		 5l5zV-1j2qH:
29.22
5l5zW-1j2qH:
26.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 9 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.41A 5l5zY-1j2qH:
29.6
5l5zZ-1j2qH:
24.7		 5l5zY-1j2qH:
31.36
5l5zZ-1j2qH:
26.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L66_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 THR H   1
ALA H  20
THR H  21
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.18A 5l66K-1j2qH:
29.9
5l66L-1j2qH:
24.8		 5l66K-1j2qH:
29.58
5l66L-1j2qH:
26.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L66_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 THR H   1
ALA H  20
THR H  21
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.18A 5l66Y-1j2qH:
29.9
5l66Z-1j2qH:
24.6		 5l66Y-1j2qH:
29.58
5l66Z-1j2qH:
26.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_H_BO2H306_1
(PROTEASOME SUBUNIT
BETA TYPE-7
PROTEASOME SUBUNIT
BETA TYPE-3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 THR H   1
ALA H  20
THR H  21
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.25A 5lf3H-1j2qH:
30.5
5lf3I-1j2qH:
28.3		 5lf3H-1j2qH:
30.00
5lf3I-1j2qH:
28.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  20
THR H  21
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.33A 5lf3K-1j2qH:
30.1
5lf3L-1j2qH:
26.4		 5lf3K-1j2qH:
33.01
5lf3L-1j2qH:
29.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_V_BO2V303_1
(PROTEASOME SUBUNIT
BETA TYPE-7
PROTEASOME SUBUNIT
BETA TYPE-3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 10 THR H   1
ALA H  20
THR H  21
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.28A 5lf3V-1j2qH:
30.5
5lf3W-1j2qH:
28.3		 5lf3V-1j2qH:
30.00
5lf3W-1j2qH:
28.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  20
THR H  21
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.34A 5lf3Y-1j2qH:
30.1
5lf3Z-1j2qH:
26.5		 5lf3Y-1j2qH:
33.01
5lf3Z-1j2qH:
29.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_B_6V8B304_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.47A 5lf7V-1j2qH:
30.5
5lf7b-1j2qH:
29.1		 5lf7V-1j2qH:
30.00
5lf7b-1j2qH:
30.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_H_6V8H305_0
(PROTEASOME SUBUNIT
BETA TYPE-3
PROTEASOME SUBUNIT
BETA TYPE-7)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  20
THR H  21
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.29A 5lf7H-1j2qH:
30.6
5lf7I-1j2qH:
28.4		 5lf7H-1j2qH:
30.00
5lf7I-1j2qH:
28.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  20
THR H  21
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.28A 5lf7K-1j2qH:
30.3
5lf7L-1j2qH:
26.5		 5lf7K-1j2qH:
33.01
5lf7L-1j2qH:
29.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_N_6V8N305_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.45A 5lf7H-1j2qH:
30.6
5lf7N-1j2qH:
29.1		 5lf7H-1j2qH:
30.00
5lf7N-1j2qH:
30.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_V_6V8V303_0
(PROTEASOME SUBUNIT
BETA TYPE-3
PROTEASOME SUBUNIT
BETA TYPE-7)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  20
THR H  21
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.30A 5lf7V-1j2qH:
30.5
5lf7W-1j2qH:
28.4		 5lf7V-1j2qH:
30.00
5lf7W-1j2qH:
28.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  20
THR H  21
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.29A 5lf7Y-1j2qH:
30.3
5lf7Z-1j2qH:
26.5		 5lf7Y-1j2qH:
33.01
5lf7Z-1j2qH:
29.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BSG_A_EFZA601_1
(REVERSE
TRANSCRIPTASE P66
SUBUNIT)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 10 VAL H  49
VAL H  97
TYR H  95
GLY H  47
TYR H  35
 CIB  H1001 (-4.0A)
None
None
CIB  H1001 (-4.4A)
None
 1.44A 6bsgA-1j2qH:
undetectable		 6bsgA-1j2qH:
16.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_B_BO2B201_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-2)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.37A 6hwdV-1j2qH:
29.7
6hwdb-1j2qH:
28.9		 6hwdV-1j2qH:
19.29
6hwdb-1j2qH:
18.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_H_BO2H301_0
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
ALA H  27
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.35A 6hwdH-1j2qH:
28.0
6hwdI-1j2qH:
28.1		 6hwdH-1j2qH:
19.29
6hwdI-1j2qH:
15.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.79A 6hwdK-1j2qH:
29.6
6hwdL-1j2qH:
25.0		 6hwdK-1j2qH:
21.05
6hwdL-1j2qH:
17.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.32A 6hwdK-1j2qH:
29.6
6hwdL-1j2qH:
25.0		 6hwdK-1j2qH:
21.05
6hwdL-1j2qH:
17.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_N_BO2N201_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-2)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 12 THR H   1
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.36A 6hwdH-1j2qH:
28.0
6hwdN-1j2qH:
29.0		 6hwdH-1j2qH:
19.29
6hwdN-1j2qH:
18.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_V_BO2V301_0
(PROTEASOME SUBUNIT
BETA TYPE-2)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 THR H   1
ALA H  27
LYS H  33
ALA H  46
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 ( 4.7A)
CIB  H1001 (-4.4A)
 0.35A 6hwdV-1j2qH:
29.7		 6hwdV-1j2qH:
19.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		5 / 11 ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.78A 6hwdY-1j2qH:
16.9
6hwdZ-1j2qH:
24.8		 6hwdY-1j2qH:
21.05
6hwdZ-1j2qH:
17.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 1j2q PROTEASOME BETA
SUBUNIT
(Archaeoglobus
fulgidus) 		6 / 11 THR H   1
ALA H  20
THR H  21
ALA H  27
LYS H  33
GLY H  47
 CIB  H1001 (-1.9A)
CIB  H1001 (-3.8A)
CIB  H1001 (-4.5A)
CIB  H1001 (-3.5A)
CIB  H1001 (-4.0A)
CIB  H1001 (-4.4A)
 0.32A 6hwdY-1j2qH:
16.9
6hwdZ-1j2qH:
24.8		 6hwdY-1j2qH:
21.05
6hwdZ-1j2qH:
17.82